In terms of targeting of Eph receptors, most progress has been made in the area of hematological malignancies with EPHA3 emerging as a putative target. Expressed aberrantly and often mutated in a ...

One key aspect of major developmental therapeutics implications in which EPHA3 in hematologic malignancies remains consistent with what is seen in other Eph-expressing cancers is the direct ...